PRESS RELEASE published on 09/17/2025 at 14:00, 4 months 27 days ago Informations privilégiées / Autres communiqués Teva et Medincell présenteront les résultats de phase 3 de l'Olanzapine LAI à Psych Congress 2025, préparant le lancement du traitement de la schizophrénie avec Teva Schizophrénie Phase 3 Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 4 months 27 days ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 5 months 2 days ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
BRIEF published on 09/12/2025 at 07:35, 5 months 2 days ago Medincell nomme trois nouveaux membres au conseil d'administration Innovation Biopharmaceutique Direction Nominations Au Conseil D'administration Medincell
PRESS RELEASE published on 09/12/2025 at 07:30, 5 months 2 days ago Inside Information / Other news releases Medincell appoints Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors, adding valuable expertise in biotech and pharmaceutical sectors Board Of Directors Medincell Dr. Sharon Mates Dr. Charles Kunsch Dr. Pascal Touchon
PRESS RELEASE published on 09/12/2025 at 07:30, 5 months 2 days ago Informations privilégiées / Autres communiqués Medincell nomme le Dr Sharon Mates, le Dr Charles Kunsch et le Dr Pascal Touchon au conseil d'administration lors de l'AG annuelle et extraordinaire. Contribution cruciale pour l'avenir de l'entreprise Conseil D'administration Medincell Dr Sharon Mates Dr Charles Kunsch Dr Pascal Touchon
BRIEF published on 09/10/2025 at 21:46, 5 months 4 days ago UZEDY® obtient l'approbation en Corée du Sud après son succès aux États-Unis Schizophrénie UZEDY Approvisionnement Médical Teva Handok Marché Coréen
BRIEF published on 09/10/2025 at 21:46, 5 months 4 days ago UZEDY® Obtains Approval in South Korea Following Success in the United States Schizophrenia UZEDY Teva Handok Medical Supply Korean Market
PRESS RELEASE published on 09/10/2025 at 21:41, 5 months 4 days ago Informations privilégiées / Autres communiqués UZEDY(R) approuvé en Corée du Sud après un lancement réussi aux États-Unis. Medincell percevra des royalties sur les ventes et est éligible à des milestones commerciaux Schizophrénie Approbation Medincell Corée Du Sud UZEDY
PRESS RELEASE published on 09/10/2025 at 21:41, 5 months 4 days ago Inside Information / Other news releases Teva Handok announces regulatory approval for UZEDY® in South Korea by Ministry of Food and Drug Safety, following successful US launch. Medincell's long-acting injectable for schizophrenia shows strong commercial performance Regulatory Approval Schizophrenia Medincell Commercial Performance Teva Handok
Published on 02/14/2026 at 01:00, 1 day 5 hours ago Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:15, 1 day 7 hours ago Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 1 day 12 hours ago Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 1 day 15 hours ago Datametrex Received $500,000 Purchase Order For Data Centre Solutions
Published on 02/14/2026 at 16:30, 13 hours 35 minutes ago Milano Cortina 2026 Licensed Candies Released Globally
Published on 02/14/2026 at 06:05, 1 day ago The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
Published on 02/13/2026 at 19:20, 1 day 10 hours ago Retail offering successfully completed and update on Euronext Growth Oslo listing
Published on 02/13/2026 at 19:01, 1 day 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/13/2026 at 18:20, 1 day 11 hours ago GLOBAL TECHNOLOGY LEADERS LAUNCH TRUSTED TECH ALLIANCE
Published on 02/13/2026 at 18:05, 1 day 12 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 1 day 12 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 1 day 12 hours ago Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 1 day 12 hours ago Nombre total d'actions et droits de vote - janvier 2026
